. 2023 Jul 28;12(4):e220223. doi: 10.1530/ETJ-22-0223
This work is licensed under a Table 1.
Clinical manifestations and measurements of patients.
| Patient | Age/gender | Clinical manifestations | TT3 (nmol/L) | TT4 (nmol/L) | TSH (μIU/mL) | FT3 (pmol/L) | FT4 (pmol/L) | TRAb (IU/L) | TPO-Ab (IU/mL) | Tg-Ab (IU/mL) | Dmax (mm) | Short-acting octreotide inhibition test |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 26/F | Polyphagia, palpitations, tremor, thermophobia, headache, exophthalmos, and goiter | 3.44 | 239.82 | 2.407 | 12.8 | 43.19 | 8.04 | >1238.00 | 890.81 | 17 | + |
| Case 2 | 47/F | Palpitations, tremor, headache, hypoplasia, and goiter | 3.98 | 201.69 | 6.854 | 12.08 | 30.05 | 5.06 | 0.32 | 1.66 | 18 | + |
| Case 3 | 45/F | Palpitations, weight loss, and amenorrhea | 4.01 | 276.86 | 4.73 | 14.59 | 60.03 | 0.654 (postoperative 3.69) | 232.73 | 14.21 | 20 | + |
| Case 4 | 51/M | Palpitations, tremor, and exophthalmos | 1.48 | 96.97 | 62.635 | 4.8 | 14.36 | <0.3 (initial positive) | 14.44 | 4.73 | 12 | − |
Normal ranges: TT3 1.01–2.48 nmol/L; TT4 69.97–152.52 nmol/L; TSH 0.49–4.91 μIU/mL; FT3 3.28–6.47 pmol/L; FT4 7.64–16.03 pmol/L; TRAb 0–1.7 IU/L; TPO-Ab 0–9 IU/mL; Tg-Ab 0–4 IU/mL.
Dmax, maximum diameter of pituitary adenomas; F, female; FT3, free tri-iodothyronine; FT4, free thyroxine; M, man; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; TRAb, thyroid-stimulating hormone receptor antibodies; TSH, thyroid-stimulating hormone; TT3, total tri-iodothyronine; TT4, total thyroxine.